Duaa Mohammed Abdulsatar, Hayfaa Mahmood Fahad, Sahar Taha Hatif, Zaid Jaafar Awad Al-Nuaimi
{"title":"Role of anti-inflammatory cytokine (IL10) in patients with chronic kidney disease.","authors":"Duaa Mohammed Abdulsatar, Hayfaa Mahmood Fahad, Sahar Taha Hatif, Zaid Jaafar Awad Al-Nuaimi","doi":"10.1177/10932607251317417","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anti-inflammatory cytokines is thought to influence the onset and course of chronic kidney disease (CKD). Particular cytokines include Interleukin-10 (IL-10), which is usually considered anti-inflammatory.</p><p><strong>Objectives: </strong>The current study designed to determine the activity of the IL10 and their roles in chronic kidney disease.</p><p><strong>Methods: </strong>This research is done, forty- five blood samples were collected from patients with chronic kidney disease and 42 volunteers. A sandwich ELISA was used to estimate the serum levels of human Interleukin-10.</p><p><strong>Results: </strong>The mean age among patient groups (males, females) it was 47.40 ± 2.96 and 62.64 ± 14.46 years, respectively. While the control groups (males, females) were 40.97 ± 1.67 and 45.25 ± 7.13 years (p > 0.05). Of the 45 patients, 20 (44.4%) were males, 25 (55.6%) females. The resulted data showed that there are no significant (p > 0.05) for the total of the mean of human IL-10 between patients and control, respectively, where the mean level of IL10 in males was 190.10 ± 15.07& 154.18 ± 8.77 (p < 0.05) respectively and 142.22 ± 12.43 & 117.04 ± 14.66 in females, but not significantly (p > 0.05), and revealed an highly increased significant in this marker during the course of the chronic kidney disease in males more than females in patients (p < 0.05).</p><p><strong>Conclusion: </strong>Can conclude from this study that decreased anti-inflammatory cytokine IL10 likely affects CKD progression and prognosis in females specifically.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"10932607251317417"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/10932607251317417","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Anti-inflammatory cytokines is thought to influence the onset and course of chronic kidney disease (CKD). Particular cytokines include Interleukin-10 (IL-10), which is usually considered anti-inflammatory.
Objectives: The current study designed to determine the activity of the IL10 and their roles in chronic kidney disease.
Methods: This research is done, forty- five blood samples were collected from patients with chronic kidney disease and 42 volunteers. A sandwich ELISA was used to estimate the serum levels of human Interleukin-10.
Results: The mean age among patient groups (males, females) it was 47.40 ± 2.96 and 62.64 ± 14.46 years, respectively. While the control groups (males, females) were 40.97 ± 1.67 and 45.25 ± 7.13 years (p > 0.05). Of the 45 patients, 20 (44.4%) were males, 25 (55.6%) females. The resulted data showed that there are no significant (p > 0.05) for the total of the mean of human IL-10 between patients and control, respectively, where the mean level of IL10 in males was 190.10 ± 15.07& 154.18 ± 8.77 (p < 0.05) respectively and 142.22 ± 12.43 & 117.04 ± 14.66 in females, but not significantly (p > 0.05), and revealed an highly increased significant in this marker during the course of the chronic kidney disease in males more than females in patients (p < 0.05).
Conclusion: Can conclude from this study that decreased anti-inflammatory cytokine IL10 likely affects CKD progression and prognosis in females specifically.
期刊介绍:
Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology under a single, cohesive theme. This includes fundamental research, applied science and clinical applications. Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors. Immunoregulatory molecules, including T cell hybridomas, will also be featured.